Rho-kinase as a potential target for the treatment of erectile dysfunction

Kanchan Chitaley, R. Clinton Webb, Thomas M. Mills

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Erectile dysfunction is a condition that is estimated to affect more than 30 million men in the United States alone. The prevalence of erectile dysfunction is increased with age and is often secondary to diseases such as depression, hypertension and diabetes. Causes of erectile dysfunction include physical injury to the cavernosum and abnormal cerebral and peripheral nervous system functioning. However, many cases of erectile dysfunction are the result of dysfunctional signaling in the cavernosal vasculature. This article will detail the important role of a vasoconstrictor mechanism mediated by the small G-protein RhoA and a downstream serine/threonine kinase, Rho-kinase, in the maintenance of penile flaccidity. Recent evidence demonstrates that inhibition of endogenous Rho-kinase initiates an erectile response in an in vivo rat model. These initial findings introduce a novel potential therapeutic approach for the treatment of erectile dysfunction.

Original languageEnglish (US)
Pages (from-to)601-606
Number of pages6
JournalDrug News and Perspectives
Volume14
Issue number10
StatePublished - Dec 1 2001
Externally publishedYes

Fingerprint

rho-Associated Kinases
Erectile Dysfunction
Therapeutics
Monomeric GTP-Binding Proteins
Protein-Serine-Threonine Kinases
Peripheral Nervous System
Vasoconstrictor Agents
Maintenance
Depression
Hypertension
Wounds and Injuries

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this

Rho-kinase as a potential target for the treatment of erectile dysfunction. / Chitaley, Kanchan; Webb, R. Clinton; Mills, Thomas M.

In: Drug News and Perspectives, Vol. 14, No. 10, 01.12.2001, p. 601-606.

Research output: Contribution to journalArticle

Chitaley, Kanchan ; Webb, R. Clinton ; Mills, Thomas M. / Rho-kinase as a potential target for the treatment of erectile dysfunction. In: Drug News and Perspectives. 2001 ; Vol. 14, No. 10. pp. 601-606.
@article{2f34a5e1f34145d6ab2be9ee876a7fc4,
title = "Rho-kinase as a potential target for the treatment of erectile dysfunction",
abstract = "Erectile dysfunction is a condition that is estimated to affect more than 30 million men in the United States alone. The prevalence of erectile dysfunction is increased with age and is often secondary to diseases such as depression, hypertension and diabetes. Causes of erectile dysfunction include physical injury to the cavernosum and abnormal cerebral and peripheral nervous system functioning. However, many cases of erectile dysfunction are the result of dysfunctional signaling in the cavernosal vasculature. This article will detail the important role of a vasoconstrictor mechanism mediated by the small G-protein RhoA and a downstream serine/threonine kinase, Rho-kinase, in the maintenance of penile flaccidity. Recent evidence demonstrates that inhibition of endogenous Rho-kinase initiates an erectile response in an in vivo rat model. These initial findings introduce a novel potential therapeutic approach for the treatment of erectile dysfunction.",
author = "Kanchan Chitaley and Webb, {R. Clinton} and Mills, {Thomas M.}",
year = "2001",
month = "12",
day = "1",
language = "English (US)",
volume = "14",
pages = "601--606",
journal = "Drug News and Perspectives",
issn = "0214-0934",
publisher = "Prous Science",
number = "10",

}

TY - JOUR

T1 - Rho-kinase as a potential target for the treatment of erectile dysfunction

AU - Chitaley, Kanchan

AU - Webb, R. Clinton

AU - Mills, Thomas M.

PY - 2001/12/1

Y1 - 2001/12/1

N2 - Erectile dysfunction is a condition that is estimated to affect more than 30 million men in the United States alone. The prevalence of erectile dysfunction is increased with age and is often secondary to diseases such as depression, hypertension and diabetes. Causes of erectile dysfunction include physical injury to the cavernosum and abnormal cerebral and peripheral nervous system functioning. However, many cases of erectile dysfunction are the result of dysfunctional signaling in the cavernosal vasculature. This article will detail the important role of a vasoconstrictor mechanism mediated by the small G-protein RhoA and a downstream serine/threonine kinase, Rho-kinase, in the maintenance of penile flaccidity. Recent evidence demonstrates that inhibition of endogenous Rho-kinase initiates an erectile response in an in vivo rat model. These initial findings introduce a novel potential therapeutic approach for the treatment of erectile dysfunction.

AB - Erectile dysfunction is a condition that is estimated to affect more than 30 million men in the United States alone. The prevalence of erectile dysfunction is increased with age and is often secondary to diseases such as depression, hypertension and diabetes. Causes of erectile dysfunction include physical injury to the cavernosum and abnormal cerebral and peripheral nervous system functioning. However, many cases of erectile dysfunction are the result of dysfunctional signaling in the cavernosal vasculature. This article will detail the important role of a vasoconstrictor mechanism mediated by the small G-protein RhoA and a downstream serine/threonine kinase, Rho-kinase, in the maintenance of penile flaccidity. Recent evidence demonstrates that inhibition of endogenous Rho-kinase initiates an erectile response in an in vivo rat model. These initial findings introduce a novel potential therapeutic approach for the treatment of erectile dysfunction.

UR - http://www.scopus.com/inward/record.url?scp=0035724390&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035724390&partnerID=8YFLogxK

M3 - Article

C2 - 12806426

AN - SCOPUS:0035724390

VL - 14

SP - 601

EP - 606

JO - Drug News and Perspectives

JF - Drug News and Perspectives

SN - 0214-0934

IS - 10

ER -